These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 21079673)

  • 1. The Mycobacterium tuberculosis drugome and its polypharmacological implications.
    Kinnings SL; Xie L; Fung KH; Jackson RM; Xie L; Bourne PE
    PLoS Comput Biol; 2010 Nov; 6(11):e1000976. PubMed ID: 21079673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pros and cons of the tuberculosis drugome approach--an empirical analysis.
    Chen FC; Liao YC; Huang JM; Lin CH; Chen YY; Dou HY; Hsiung CA
    PLoS One; 2014; 9(6):e100829. PubMed ID: 24971632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining cheminformatics methods and pathway analysis to identify molecules with whole-cell activity against Mycobacterium tuberculosis.
    Sarker M; Talcott C; Madrid P; Chopra S; Bunin BA; Lamichhane G; Freundlich JS; Ekins S
    Pharm Res; 2012 Aug; 29(8):2115-27. PubMed ID: 22477069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulators targeting protein-protein interactions in Mycobacterium tuberculosis.
    Luo G; Ming T; Yang L; He L; Tao T; Wang Y
    Microbiol Res; 2024 Jul; 284():127675. PubMed ID: 38636239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three-dimensional models of Mycobacterium tuberculosis proteins Rv1555, Rv1554 and their docking analyses with sildenafil, tadalafil, vardenafil drugs, suggest interference with quinol binding likely to affect protein's function.
    Dash P; Bala Divya M; Guruprasad L; Guruprasad K
    BMC Struct Biol; 2018 Apr; 18(1):5. PubMed ID: 29669541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recognizing drug targets using evolutionary information: implications for repurposing FDA-approved drugs against Mycobacterium tuberculosis H37Rv.
    Ramakrishnan G; Chandra NR; Srinivasan N
    Mol Biosyst; 2015 Dec; 11(12):3316-31. PubMed ID: 26429199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increasing the structural coverage of tuberculosis drug targets.
    Baugh L; Phan I; Begley DW; Clifton MC; Armour B; Dranow DM; Taylor BM; Muruthi MM; Abendroth J; Fairman JW; Fox D; Dieterich SH; Staker BL; Gardberg AS; Choi R; Hewitt SN; Napuli AJ; Myers J; Barrett LK; Zhang Y; Ferrell M; Mundt E; Thompkins K; Tran N; Lyons-Abbott S; Abramov A; Sekar A; Serbzhinskiy D; Lorimer D; Buchko GW; Stacy R; Stewart LJ; Edwards TE; Van Voorhis WC; Myler PJ
    Tuberculosis (Edinb); 2015 Mar; 95(2):142-8. PubMed ID: 25613812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the progress of Mycobacterium tuberculosis H37Rv structural genomics.
    Fang Z; van der Merwe RG; Warren RM; Schubert WD; Gey van Pittius NC
    Tuberculosis (Edinb); 2015 Mar; 95(2):131-6. PubMed ID: 25578513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In silico structure-based design of a novel class of potent and selective small peptide inhibitor of Mycobacterium tuberculosis Dihydrofolate reductase, a potential target for anti-TB drug discovery.
    Kumar M; Vijayakrishnan R; Subba Rao G
    Mol Divers; 2010 Aug; 14(3):595-604. PubMed ID: 19697148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In silico discovery and virtual screening of multi-target inhibitors for proteins in Mycobacterium tuberculosis.
    Speck-Planche A; Kleandrova VV; Luan F; Cordeiro MN
    Comb Chem High Throughput Screen; 2012 Sep; 15(8):666-73. PubMed ID: 22452349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug resistance mechanisms and novel drug targets for tuberculosis therapy.
    Islam MM; Hameed HMA; Mugweru J; Chhotaray C; Wang C; Tan Y; Liu J; Li X; Tan S; Ojima I; Yew WW; Nuermberger E; Lamichhane G; Zhang T
    J Genet Genomics; 2017 Jan; 44(1):21-37. PubMed ID: 28117224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative analyses of the proteins from Mycobacterium tuberculosis and human genomes: Identification of potential tuberculosis drug targets.
    Sridhar S; Dash P; Guruprasad K
    Gene; 2016 Mar; 579(1):69-74. PubMed ID: 26762852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perspective: Challenges and opportunities in TB drug discovery from phenotypic screening.
    Manjunatha UH; Smith PW
    Bioorg Med Chem; 2015 Aug; 23(16):5087-97. PubMed ID: 25577708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A whole genome bioinformatic approach to determine potential latent phase specific targets in Mycobacterium tuberculosis.
    Defelipe LA; Do Porto DF; Pereira Ramos PI; Nicolás MF; Sosa E; Radusky L; Lanzarotti E; Turjanski AG; Marti MA
    Tuberculosis (Edinb); 2016 Mar; 97():181-92. PubMed ID: 26791267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoteric advancement in TB drugs and an overview on the anti-tubercular role of peptides through computational approaches.
    Khusro A; Aarti C; Barbabosa-Pliego A; Salem AZM
    Microb Pathog; 2018 Jan; 114():80-89. PubMed ID: 29174699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteomic characterization of Mycobacterium tuberculosis reveals potential targets of bostrycin.
    Yuan P; He L; Chen D; Sun Y; Ge Z; Shen D; Lu Y
    J Proteomics; 2020 Feb; 212():103576. PubMed ID: 31706025
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Sawicki R; Ginalska G
    Future Med Chem; 2019 Aug; 11(16):2193-2203. PubMed ID: 31538522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In silico analyses for the discovery of tuberculosis drug targets.
    Chung BK; Dick T; Lee DY
    J Antimicrob Chemother; 2013 Dec; 68(12):2701-9. PubMed ID: 23838951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H
    Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.